Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 4/2009

01-10-2009 | Conference Paper

Breast cancer risk assessment for possible tailored screening for Japanese women

Authors: Yasuhiro Tamaki, Yasuyuki Kotsuma, Yasuo Miyoshi, Shinzaburo Noguchi

Published in: Breast Cancer | Issue 4/2009

Login to get access

Abstract

Accurate risk assessment for individual women is essential for effective screening of breast cancer (BC) in Japan, because the incidence of BC is still lower than in Western countries. We investigated various new risk factors of BC by means of case control studies and found that serum estrone and adiponectine levels as well as mammographic breast density were significantly correlated to BC risk. Combining these new factors and conventional risk factors of BC may result in a new and useful risk assessment tool, may improve the cost-effectiveness of screening, and may enable us to reduce the BC mortality of Japanese women.
Literature
1.
Quinn M, Allen E. Changes in incidence of and mortality from breast cancer in England and Wales since introduction of screening. United Kingdom Association of Cancer Registries. BMJ. 1995;311:1391–5.PubMed
2.
Cronin KA, Feuer EJ, Clarke LD, Plevritis SK. Impact of adjuvant therapy and mammography on US mortality from 1975 to 2000: comparison of mortality results from the CISNET breast cancer base case analysis. J Natl Cancer Inst. 2006;36:112–21.
3.
Coldman A, Phillips N, Warren L, Kan L. Breast cancer mortality after screening mammography in British Columbia women. Int J Cancer. 2007;120:1076–80.PubMedCrossRef
4.
Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ. 2007;335:1134.PubMedCrossRef
5.
Ahn J, Schatzkin A, Lacey JV Jr, Albanes D, Ballard-Barbash R, Adams KF, et al. Adiposity, adult weight change, and postmenopausal breast cancer risk. Arch Intern Med. 2007;167:2091–102.PubMedCrossRef
6.
Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569–78.PubMedCrossRef
7.
Cuzick J. Hormone replacement therapy and the risk of breast cancer. Eur J Cancer. 2008;44:2344–9.PubMedCrossRef
8.
Brinton LA, Richesson D, Leitzmann MF, Gierach GL, Schatzkin A, Mouw T, et al. Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Study cohort. Cancer Epidemiol Biomarkers Prev. 2008;17:3150–60.PubMedCrossRef
9.
Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97:1652–62.PubMed
10.
Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen versus raloxifene on the risk of development breast cancer and other disease outcomes: the NSABP study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295:2727–41.PubMedCrossRef
11.
Miyoshi Y, Tanji Y, Taguchi T, Tamaki Y, Noguchi S. Association of serum estrone levels with estrogen receptor-positive breast cancer risk in postmenopausal Japanese women. Clin Cancer Res. 2003;9:2229–33.PubMed
12.
Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrine Metab. 2001;86:3815–9.CrossRef
13.
Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2004;24:29–33.PubMedCrossRef
14.
Miyoshi Y, Funahashi T, Kihara S, Taguchi T, Tamaki Y, Matsuzawa Y, et al. Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res. 2003;9:5699–704.PubMed
15.
Dos Santos E, Benaitreau D, Diedonne MN, Leneveu MC, Serazin V, Giudicelli Y, et al. Adiponectin mediates an antiproliferative response in human MDA-MB 231 breast cancer cells. Oncol Rep. 2008;20:971–7.PubMed
16.
Grossmann ME, Nkhata KJ, Mizuno NK, Ray A, Cleary MP. Effects of adiponectin on breast cancer cell growth and signaling. Br J Cancer. 2008;98:370–9.PubMedCrossRef
17.
Wolfe JN. Breast patterns as index of risk of breast cancer. Am J Roentgenol. 1976;126:1130–9.
18.
Wolfe JN, Saftlas AF, Salane M. Mammographic parenchymal patterns and quantitative evaluation of mammographic densities: a case–control study. Am J Roentgenol. 1987;148:1087–92.
19.
Saftlas AF, Hoover RN, Brinton LA, Szkio M, Olson DR, Salane M, et al. Mammographic densities and risk of breast cancer. Cancer. 1991;67:2883–8.CrossRef
20.
Boyed NF, Byng JW, Jong RA, Fishell EK, Little LE, Miller AB, et al. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst. 1995;87:670–5.CrossRef
21.
Nagao Y, Kawaguchi Y, Sugiyama Y, Saji S, Kashiki Y. Relationship between mammographic density and the risk of breast cancer in Japanese women: a case–control study. Breast Cancer. 2003;10:228–33.PubMedCrossRef
22.
Nagata C, Matsubara T, Fujita H, Nagao Y, Shibuya C, Kashiki Y, et al. Mammographic density and the risk of breast cancer in Japanese women. Br J Cancer. 2005;92:2102–6.PubMedCrossRef
23.
Kotsuma Y, Tamaki Y, Nishimura T, Tsubai M, Ueda S, Shimazu K, et al. Quantitative assessment of mammographic density and breast cancer risk for Japanese women. Breast. 2008;17:27–35.PubMedCrossRef
24.
Gabe R, Duffy SW. Evaluation of service screening mammography in practice: the impact on breast cancer mortality. Ann Oncol. 2005;16(Suppl 2):ii153–62.PubMedCrossRef
25.
Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81:1879–86.PubMedCrossRef
26.
Miyoshi Y, Ando A, Hasegawa S, Ishitobi M, Yamamura J, Irahara N, et al. Association of genetic polymorphism in CYP19 and CYP1A1 with the oestrogen receptor-positive breast cancer risk. Eur J Cancer. 2003;39:2531–7.PubMedCrossRef
27.
Noma C, Miyoshi Y, Taguchi T, Tamaki Y, Noguchi S. Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women. Cancer Lett. 2004;210:197–203.PubMedCrossRef
28.
Ishitobi M, Miyoshi Y, Ando A, Hasegawa S, Egawa C, Tamaki Y, et al. Association of BRCA2 polymorphism at codon 784 (Met/Val) with breast cancer risk and prognosis. Clin Cancer Res. 2003;9:1376–80.PubMed
29.
Randall D, Morrell S, Taylor R, Hung WT. Annual or biennial mammography screening for women at a higher risk with a family history of breast cancer: prognostic indicators of screen-detected cancers in New South Wales, Australia. Cancer Causes Control, 2008 (Epub ahead of print).
30.
White E, Miqlioretti DL, Yankaskas BC, Rosenberg RD, Kerlikowske K, Saba L, et al. Biennial versus annual mammography and the risk of late-stage breast cancer. J Natl Cancer Inst. 2004;96:1832–9.PubMedCrossRef
31.
The Breast Screening Frequency Trial Group. The frequency of breast cancer screening: results from the UKCCR randomized trial. Eur J Cancer. 2002;38:1458–64.CrossRef
32.
Berg WA. Tailored supplemental screening for breast cancer: what now and what next? Am J Roentogenol. 2009;192:390–9.CrossRef
33.
Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, et al. American Cancer Society Guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57:75–89.PubMedCrossRef
Metadata
Title
Breast cancer risk assessment for possible tailored screening for Japanese women
Authors
Yasuhiro Tamaki
Yasuyuki Kotsuma
Yasuo Miyoshi
Shinzaburo Noguchi
Publication date
01-10-2009
Publisher
Springer Japan
Published in
Breast Cancer / Issue 4/2009
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-009-0121-0

Other articles of this Issue 4/2009

Breast Cancer 4/2009 Go to the issue

Special Feature

Recent trends of HER-2 testing and trastuzumab therapy for breast cancer

Conference Paper

Clinical significance of basal-like subtype in triple-negative breast cancer

Conference Paper

Estrogen receptor-β status influences clinical outcome of triple-negative breast cancer

Conference Paper

From standardization to personalization in breast cancer treatment

Conference Paper

Algorithm for in vitro diagnostic multivariate index assay

Original Article

Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits